Patents by Inventor Tobias Suter

Tobias Suter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210002382
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: February 11, 2020
    Publication date: January 7, 2021
    Applicant: Roche Glycart AG
    Inventors: Pablo UMAÑA, Peter BRÜNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÜNTENER, Ekkehard MÖSSNER
  • Patent number: 10816525
    Abstract: A method using a gas reservoir and a critical nozzle for determining physical properties and/or quantities relevant to combustion of gas or gas mixtures, the method includes: flowing a gas or gas mixture under pressure from the gas reservoir through the critical nozzle; measuring pressure drop in the gas reservoir as a function of time; determining a gas property factor (?*), dependent on physical properties of the gas or gas mixture, based on the measured values of the pressure drop; and determining a desired physical property or quantity relevant to combustion based on the gas property factor (?*) through correlation.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: October 27, 2020
    Assignee: MEMS AG
    Inventors: Philippe Pretre, Andreas Kempe, Tobias Suter
  • Publication number: 20170261480
    Abstract: A method using a gas reservoir and a critical nozzle for determining physical properties and/or quantities relevant to combustion of gas or gas mixtures, the method includes: flowing a gas or gas mixture under pressure from the gas reservoir through the critical nozzle; measuring pressure drop in the gas reservoir as a function of time; determining a gas property factor (?*), dependent on physical properties of the gas or gas mixture, based on the measured values of the pressure drop; and determining a desired physical property or quantity relevant to combustion based on the gas property factor (?*) through correlation.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 14, 2017
    Inventors: Philippe PRETRE, Andreas KEMPE, Tobias SUTER
  • Publication number: 20170176405
    Abstract: A method to determine a physical property or a quantity of gas related to combustion including: flowing a gas from a reservoir through a critical nozzle and past a microthermal sensor wherein the mass flow of the gas through the critical nozzle is the same as the mass flow through the microthermal sensor; measuring the pressure drop in the reservoir as a function of time; deriving a first gas property factor based on a time constant of the pressure drop; determining a second gas property factor which depends from a flow signal generated by the microthermal sensor; determining a thermal conductivity of the gas; and determining the physical property or quantity based on a correlation between the physical property or quantity, and the first and/or second gas property factors and the thermal conductivity.
    Type: Application
    Filed: March 1, 2017
    Publication date: June 22, 2017
    Inventors: Philippe PRETRE, Andreas KEMPE, TOBIAS SUTER
  • Patent number: 9612229
    Abstract: A method for determining physical properties of combustion including: flowing a gas a critical nozzle and past a microthermal sensor wherein the mass flow of the gas through the critical nozzle is the same as the mass flow through the microthermal sensor; measuring the pressure drop in a reservoir of gas flowing to the nozzle; determining a first gas property factor based on the measured pressure drop; determining a second gas property factor based on a flow signal generated by the microthermal sensor; determining a thermal conductivity of the gas using the microthermal sensor; and determining a physical property of the combustion based on a correlation of the first and/or second gas property factors and the thermal conductivity.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: April 4, 2017
    Assignee: MEMS AG
    Inventors: Philippe Pretre, Andreas Kempe, Tobias Suter
  • Patent number: 9296820
    Abstract: The present invention relates to nucleic acids encoding anti-CD20 antigen binding molecules (ABMs). In particular embodiments, the present invention relates to nucleic acid encoding recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In some embodiments, the invention relates to an isolated polynucleotide comprising a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:40; SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76. In addition, the present invention relates to vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: March 29, 2016
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Peter Brünker, Claudia Ferrara Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
  • Publication number: 20160076009
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: July 31, 2015
    Publication date: March 17, 2016
    Inventors: Pablo UMAÑA, Peter BRÜNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÜNTENER, Ekkehard MÖSSNER
  • Publication number: 20160075793
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: July 31, 2015
    Publication date: March 17, 2016
    Inventors: Pablo UMAÑA, Peter BRÜNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÜNTENER, Ekkehard MÖSSNER
  • Publication number: 20160075794
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: July 31, 2015
    Publication date: March 17, 2016
    Inventors: Pablo UMAÑA, Peter Brünker, Claudia FERRARA KOLLER, Tobias SUTER, Ursula Püntener, Ekkehard Mössner
  • Publication number: 20140345363
    Abstract: A method for determining physical properties of combustion including: flowing a gas a critical nozzle and past a microthermal sensor wherein the mass flow of the gas through the critical nozzle is the same as the mass flow through the microthermal sensor; measuring the pressure drop in a reservoir of gas flowing to the nozzle; determining a first gas property factor based on the measured pressure drop; determining a second gas property factor based on a flow signal generated by the microthermal sensor; determining a thermal conductivity of the gas using the microthermal sensor; and determining a physical property of the combustion based on a correlation of the first and/or second gas property factors and the thermal conductivity.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 27, 2014
    Inventors: Philippe PRETRE, Andreas KEMPE, Tobias SUTER
  • Patent number: 8883980
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 11, 2014
    Assignee: Roche Glycart AG
    Inventors: Pablo Umaña, Peter Brünker, Claudia Ferrera Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
  • Patent number: 8859234
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: October 14, 2014
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Peter Bruenker, Claudia Ferrara, Tobias Suter
  • Patent number: 8367374
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: February 5, 2013
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Peter Bruenker, Claudia Ferrara, Tobias Suter
  • Publication number: 20090010921
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 8, 2009
    Applicant: GlycArt Biotechnology AG
    Inventors: Pablo Umana, Peter Brunker, Claudia Ferrara, Tobias Suter, Ursula Puntener, Ekkehard Mossner
  • Publication number: 20050123546
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: November 5, 2004
    Publication date: June 9, 2005
    Applicant: GlycArt Biotechnology AG
    Inventors: Pablo Umana, Peter Brunker, Claudia Ferrara, Tobias Suter, Ursula Puntener, Ekkehard Mossner
  • Publication number: 20040241817
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: January 22, 2004
    Publication date: December 2, 2004
    Applicant: GlycArt Biotechnology AG
    Inventors: Pablo Umana, Peter Bruenker, Claudia Ferrara, Tobias Suter